Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 10 for:    "Lens Disease" | "Phenylephrine"

Comparison of Epinephrine and Phenylephrine/Ketorolac With Regards to Pupil Size

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02895035
Recruitment Status : Terminated (Data analysis was never performed by sub-investigator)
First Posted : September 9, 2016
Last Update Posted : November 6, 2019
Sponsor:
Information provided by (Responsible Party):
Seth M Pantanelli, Milton S. Hershey Medical Center

Brief Summary:
The objective of this study is to compare the maintenance of intraoperative mydriasis during cataract surgery between two drugs: epinephrine, which has routinely been used for decades, and Omidria, a newly FDA approved combination drug of phenylephrine and ketorolac. Patients undergoing cataract surgery that are enrolled in the trial will randomly receive one of the drugs in one eye, and the other eye will receive the drug during the subsequent cataract surgery.

Condition or disease Intervention/treatment Phase
Cataract Drug: Phenylephrine-ketorolac Drug: Epinephrine Phase 4

Detailed Description:

Cataract remains a leading cause of correctable blindness worldwide. Over 3.5 million cataract surgeries in the United States and 20 million cataract surgeries worldwide are performed every year. Cataract surgery is performed by making a small incision, removing the cataractous lens, most often through the process of phacoemulsification, and replacement with an intraocular lens. Like all surgeries, adequate exposure and field of view is vital for a safe and effective surgery. In cataract surgery, the field of view is limited by the diameter of the pupil. Several different drugs, such as cyclopentolate, tropicamide, phenylephrine, and epinephrine are utilized to maintain dilation (mydriasis) of the pupil during surgery.

There are currently two prospective randomized controlled trials comparing phenylephrine/ketorolac to placebo in the published literature. Both of these studies demonstrated that phenylephrine/ketorolac is superior to placebo for the maintenance of mydriasis during cataract surgery. Epinephrine has been the standard of care for intraoperative mydriasis. Phenylephrine/ketorolac (Omidria) is a newly FDA-approved additive for the maintenance of intraoperative mydriasis, but there are currently no published studies comparing epinephrine to phenylephrine/ketorolac for maintenance of mydriasis during cataract surgery.

While both of these drugs have been shown to be superior to placebo for the maintenance of mydriasis, there is a significant cost difference between epinephrine, which has been used for many years, and phenylephrine/ketorolac, which gained FDA approval in 2014. One 4 mL vial of Omidria® is utilized for one cataract surgery, which costs $465.

The primary endpoint to be measured in the study is the mean area under the curve change from baseline in pupil diameter over time to the end of cataract surgery.

Secondary endpoints will be maximum intraoperative pupil constriction, subjects with pupil diameter less than 6.5 mm at any during surgery, subjects with pupil less than 6.0 mm during cortical clean-up, and subjects with greater than 2.5 mm of pupillary constriction at any time during surgery.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 61 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Other
Official Title: Prospective Comparison of Epinephrine and Phenylephrine/Ketorolac (Omidria®) Additives With Regards to Intraoperative Pupil Size
Actual Study Start Date : September 1, 2016
Actual Primary Completion Date : December 31, 2018
Actual Study Completion Date : December 31, 2018


Arm Intervention/treatment
Active Comparator: Epinephrine
Epinephrine is the intracameral additive during cataract surgery.
Drug: Epinephrine
Epinephrine is a nonselective adrenergic agonist added to the irrigation solution during cataract surgery.

Active Comparator: Omidria
Omidria is the intracameral additive during cataract surgery.
Drug: Phenylephrine-ketorolac
Pehnylephrine-ketorolac is a combination of an alpha-one agonist (phenylephrine) and an NSAID (ketorolac). One 4-mL bottle of 1% phenylephrine/3% ketorolac is added to the irrigation solution during cataract surgery.
Other Name: Omidria




Primary Outcome Measures :
  1. the mean area under the curve change from baseline in pupil diameter over time to the end of cataract surgery [ Time Frame: N/A (during cataract surgery) ]

Secondary Outcome Measures :
  1. maximum intraoperative pupil constriction [ Time Frame: N/A (during cataract surgery) ]
  2. percentage of subjects with pupil diameter less than 6.5 mm at any during surgery [ Time Frame: N/A (during cataract surgery) ]
  3. percentage of subjects with pupil less than 6.0 mm during cortical clean-up [ Time Frame: N/A (during cataract surgery) ]
  4. percentage of subjects with greater than 2.5 mm of pupillary constriction at any time during surgery [ Time Frame: N/A (during cataract surgery) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who are older than 18 years of age
  • Patients who are planned to undergo bilateral cataract surgery
  • Patients with baseline IOP of 5 - 22 mm Hg
  • Medicare insurance*

    • There is a significant cost difference between our two study drugs. Therefore, Medicare insurance is part of our inclusion criteria, because there is a pass-through reimbursement in place to cover the cost of phenylephrine/ketorolac. Other insurances (for example, Aetna Better Health, Highmark Freedom, Gateway) have variable or poor coverage for phenylephrine/ketorolac, which would leave the medical center responsible for the cost. Patients can never be held responsible for the cost of the medication because it is included in "covered services" for cataract surgery billing.

Exclusion Criteria:

  • Patients who are planned to undergo only unilateral cataract surgery
  • Patients who are planned to undergo cataract surgery and another surgical procedure in the same operation (eg. combined cataract and glaucoma surgery)
  • Patients with concurrent clinically significant disease, connective tissue disease, abnormal blood pressure at screening, narrow-angle or unstable glaucoma or treatment with prostaglandins, uncontrolled chronic eye disease or active corneal pathology or scarring
  • Patients with history of iritis or trauma with iris damage
  • Patients with recent eye surgery (non-laser surgery within 3 months or laser surgery within 30 days prior to study surgery)
  • Patients with clinically significant hypersensitivity to the study medications
  • Patients who have used pilocarpine (a pupil constrictor) within 6 months prior to surgery

Layout table for additonal information
Responsible Party: Seth M Pantanelli, Principal Investigator, Milton S. Hershey Medical Center
ClinicalTrials.gov Identifier: NCT02895035     History of Changes
Other Study ID Numbers: 00005630
First Posted: September 9, 2016    Key Record Dates
Last Update Posted: November 6, 2019
Last Verified: November 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Lens Diseases
Phenylephrine
Oxymetazoline
Cataract
Eye Diseases
Ketorolac
Ketorolac Tromethamine
Epinephrine
Racepinephrine
Epinephryl borate
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Mydriatics
Sympathomimetics
Vasoconstrictor Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Anti-Inflammatory Agents